What is BioScience Health Innovations Current Ratio?
BioScience Health InnovationsBHIC -0.48%47 Current Ratio is 11.86 as of Mar. 2026, which is 206% above its 10-year median of 3.88. GuruFocus rates BHIC with a GF Score™ of 47/100 and a GF Value™ of $164.84 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 680 Healthcare Providers & Services companies, BioScience Health Innovations ranks better than 96.76% on this metric.
BioScience Health Innovations has a current ratio of 11.86. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for BioScience Health Innovations's Current Ratio or its related term are showing as below:
BHIC'
s Current Ratio Range Over the Past 10 Years
Min: 0.25 Med: 3.88 Max: 21.74
Current: 11.86
During the past 7 years, BioScience Health Innovations's highest Current Ratio was 21.74. The lowest was 0.25. And the median was 3.88.
BHIC's Current Ratio is ranked better than 96.76% of 680
companies
in the Healthcare Providers & Services industry
Industry Median: 1.47
vs BHIC: 11.86
BioScience Health Innovations (OTCPK:BHIC) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
BioScience Health Innovations Current Ratio Related Terms
BioScience Health Innovations Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BHIC vs SHFH, PETS, SCNX: Current Ratio Comparison
For the Pharmaceutical Retailers subindustry, BioScience Health Innovations's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioScience Health Innovations Current Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, BioScience Health Innovations's Current Ratio distribution charts can be found below:
* The bar in red indicates where BioScience Health Innovations's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioScience Health Innovations (BHIC) has a Current Ratio of 11.86 as of Mar. 2026. This is 206% above median its historical median of 3.88. Over the past decade, BioScience Health Innovations' Current Ratio has ranged from 0.25 to 21.74. According to the industry distribution chart, BioScience Health Innovations ranks #22 out of 680 companies in the Healthcare Providers & Services industry, placing it in the top 3.2%.
Is BioScience Health Innovations' Current Ratio too high?
BioScience Health Innovations' current Current Ratio of 11.86 is 206% above median its 10-year median of 3.88. Over the past 10 years, this metric has ranged from a low of 0.25 to a high of 21.74. The Healthcare Providers & Services industry median Current Ratio is 1.47. BioScience Health Innovations' value of 11.86 is 706.8% above this industry median. Based on the distribution chart, BioScience Health Innovations ranks #22 out of 680 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, BioScience Health Innovations has a GF Score™ of 47/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BioScience Health Innovations' Current Ratio compare to SHFH and PETS?
According to the Healthcare Providers & Services industry distribution chart, BioScience Health Innovations ranks #22 out of 680 companies for Current Ratio. This places BioScience Health Innovations in the top 3% of its industry — outperforming the majority of peers. The industry median Current Ratio is 1.47. BioScience Health Innovations' value of 11.86 is 706.8% above this benchmark. Historically, BioScience Health Innovations' own Current Ratio has ranged from 0.25 to 21.74 over the past decade. While the company's 10-year median is 3.88 vs. the industry median of 1.47, BioScience Health Innovations has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Healthcare Providers & Services company?
The median Current Ratio among Healthcare Providers & Services companies is 1.47, based on 680 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioScience Health Innovations's current Current Ratio of 11.86 is 706.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Healthcare Providers & Services industry, the median Current Ratio is 1.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioScience Health Innovations's current Current Ratio is 11.86, which is 206% above median its own 10-year median of 3.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioScience Health Innovations stock overvalued right now?
Based on GuruFocus' analysis, BioScience Health Innovations (BHIC) is currently considered Possible Value Trap. The stock's GF Value™ is $164.84, compared to a current price of $4.33 — trading 97.4% below its estimated fair value. The current Current Ratio is 11.86, which is 206% above median its 10-year median of 3.88 and 706.8% above the Healthcare Providers & Services industry median of 1.47. BioScience Health Innovations' overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For BioScience Health Innovations (BHIC), the current Current Ratio is 11.86 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioScience Health Innovations (BHIC) Overvalued in 2026?
Based on GuruFocus' analysis, BioScience Health Innovations stock appears to be undervalued.
The current stock price of $4.33 is trading 97.4% below its estimated GF Value™ of $164.84.
GuruFocus considers BioScience Health Innovations to be Possible Value Trap.
Key valuation signals for BHIC:
Current Ratio: 11.86 (206% above median its 10-year median of 3.88)
GF Value™: $164.84 vs. price of $4.33 (97.4% below fair value)
Industry Position: 706.8% above the Healthcare Providers & Services median (#22 of 680)
No single metric tells the full story. See the BHIC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioScience Health Innovations Business Description
BioScience Health Innovations Inc is engaged in full-scale operations as a distributor and generates revenue. The company's main business is to sell clinically tested, affordably priced products to naturally battle the onslaught of bacteria and viruses through online sales and various other distribution channels. The company develops, manufactures, and distributes science-backed nutritional supplements and delivery systems targeting cellular health, mitochondrial optimization, hormonal balance, and longevity.
47GF Score
Get the complete analysis for BHIC
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BHIC has been successfully added to your 
